Peptonic Medical
Stage
Series A | AliveTotal Raised
$2.1MAbout Peptonic Medical
Peptonic Medical is developing estrogen-free pharmaceuticals for treatment of vaginal atrophy. The patented treatments are based on local, vaginal application of oxytocin. The company's vision is to make the naturally occurring hormone, oxytocin, into the leading treatment for women suffering from vaginal atrophy during menopause. Four different clinical studies have been performed. Three of which were randomized, double blind, and placebo controlled. The studies have shown positive effects on local signs of vaginal atrophy within the vaginal wall and a reduction of symptoms.
Missing: Peptonic Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Peptonic Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Peptonic Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Peptonic Medical is included in 2 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
1,484 items
Startups focused on providing products and services catering to women's health and wellbeing.
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Peptonic Medical Patents
Peptonic Medical has filed 2 patents.
The 3 most popular patent topics include:
- Estranes
- Estrogens
- Gynaecology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/23/2018 | Psychiatric diagnosis, Gynaecology, Estrogens, Estranes, Syndromes | Application |
Application Date | 5/23/2018 |
|---|---|
Grant Date | |
Title | |
Related Topics | Psychiatric diagnosis, Gynaecology, Estrogens, Estranes, Syndromes |
Status | Application |
Latest Peptonic Medical News
Jan 24, 2023
PEPTONIC Medical AB Tue, Jan 24, 2023 14:59 CET Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests Peptonic has signed an exclusive distributor agreement with Windsor Pharmaceutical for countries in Central America. The contract spans over four years and includes Peptonic Medical self tests for vaginal infections and amniotic leakage. The products will be sold under Windsor Pharmaceuticals own brand Amniotest. Windsor Pharmaceutical is a pharmaceutical company founded 2016 with a specific focus on women’s health in Central America. The company has an extensive experience of registering as well as getting reimbursement for its range of products. - We are very pleased with having landed an agreement with Windsor Pharmaceutical. That the products have gotten reimbursement and will be readily available for women with an early launch is very exciting, say’s Erik Sundquist CEO of Peptonic Medical - Peptonic Medical has a very interesting range of self tests which we are very excited to build the business for in a region where we have very extensive experience of women’s health and hospital health care systems, says Christian Naumann, CEO and Founder of Windsor Pharmaceutical VagiVital VS is a clinically proven self test that diagnoses vaginal infection with 92% accuracy. The test is carried out on vaginal fluid and indicates the answer within 30 seconds. VagiVital AL is a clinically proven self test that can detect amniotic leakage with 97% accuracy. The test consists of a pantyliner with a patented biofilm on its surface. The result is indicated with a color change 15 minutes after the pantyliner has become wet. Peptonic continues to meet strong interest from international distributors concerning its clinically proven vaginal self tests. The agreement with Windsor is additional evidence that the company’s solutions are sought after and another quality stamp of its medical device products. The launch is expected in q2 this year. Erik Sundquist, CEO E-post: erik.sundquist@peptonicmedical.se ABOUT Peptonic Medical AB Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The business area "Medical Consumer" is based on clinically proven intimate self-care and constitutes the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on sustainable menstrual products and is sold under the Lunette brand. The company was founded in 2009 and the stock has been traded since 2014 on Spotlight (www.spotlightstockmarket.com) in Stockholm
Peptonic Medical Frequently Asked Questions (FAQ)
Where is Peptonic Medical's headquarters?
Peptonic Medical's headquarters is located at Gustavslundsvägen 143, Bromma.
What is Peptonic Medical's latest funding round?
Peptonic Medical's latest funding round is Series A.
How much did Peptonic Medical raise?
Peptonic Medical raised a total of $2.1M.
Who are the investors of Peptonic Medical?
Investors of Peptonic Medical include Almi Invest.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.